Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICER Eyes Gene Therapy: Category-wide Policy In Works As Spark Moves To Approval

Executive Summary

Institute for Clinical and Economic Review launches value assessment of Spark's blindness treatment vortigene neparvovec, the first gene therapy likely to reach the US market, in an effort to facilitate development of coverage policies.

Advertisement

Related Content

Valuing Drugs In The US: How We're Doing And What's Ahead
Spark's Gene Therapy Is On The Cusp Of Approval; Now It Gets Interesting
Spark Therapeutics' Vision Loss Gene Therapy Gets FDA Panel Review
ICER's Ambitious 2018 Review Agenda Takes On Groundbreaking Treatments

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120894

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel